Literature DB >> 15703835

PKC-mediated survival signaling in breast carcinoma cells: a role for MEK1-AP1 signaling.

Christopher B Weldon1, Amy McKee, Bridgette M Collins-Burow, Lilia I Melnik, Aline B Scandurro, John A McLachlan, Matthew E Burow, Barbara S Beckman.   

Abstract

The ability of peptide hormones, as well as the protein kinase C (PKC)-activating phorbol ester (PMA), to protect cells from apoptosis has been demonstrated to occur through activation of cellular signaling pathways such as the mitogen-activated protein kinase (MAPK) and phosphatidyl-inositol-3 kinase (PI3K) families. Here we demonstrate that tumor necrosis factor alpha (TNF)-induced apoptosis is suppressed by treatment with PMA in MCF-7 breast carcinoma cells. Reversal of the PMA survival effect with the classical isoform-specific PKC inhibitor, Go 6976, or the selective mitogen-activated protein kinase kinase (MEK) inhibitor, PD 098059, suggested a partial requirement for PKCalpha and the Erk cascade in MCF-7 cell survival. The ability of these agents to block PMA-mediated cell survival was also correlated with a suppression of PMA-induced AP-1 activity. Some naturally occurring flavonoid compounds such as apigenin can function to block cell signaling cascades such as MAPK. The ability of apigenin to block PMA-mediated cell survival was similarly correlated with suppression of PMA-stimulated AP-1 activity. Our results strongly suggest that PKC- and Erk-dependent pathways are critical components of the cell survival cascade function in suppression of TNF-induced apoptosis in MCF-7 cells. The ability of natural dietary flavonoids such as apigenin to affect cell survival pathways may represent an important aspect of the proposed anti-tumor effects of these compounds.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15703835

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  10 in total

1.  Membrane estrogen signaling enhances tumorigenesis and metastatic potential of breast cancer cells via estrogen receptor-α36 (ERα36).

Authors:  Reyhaan A Chaudhri; Rene Olivares-Navarrete; Natalia Cuenca; Agreen Hadadi; Barbara D Boyan; Zvi Schwartz
Journal:  J Biol Chem       Date:  2012-01-13       Impact factor: 5.157

2.  Differential up-regulation of MAP kinase phosphatases MKP3/DUSP6 and DUSP5 by Ets2 and c-Jun converge in the control of the growth arrest versus proliferation response of MCF-7 breast cancer cells to phorbol ester.

Authors:  Caroline E Nunes-Xavier; Céline Tárrega; Rocío Cejudo-Marín; Jeroen Frijhoff; Asa Sandin; Arne Ostman; Rafael Pulido
Journal:  J Biol Chem       Date:  2010-06-16       Impact factor: 5.157

Review 3.  Apigenin: a promising molecule for cancer prevention.

Authors:  Sanjeev Shukla; Sanjay Gupta
Journal:  Pharm Res       Date:  2010-03-20       Impact factor: 4.200

4.  Plant flavone apigenin: An emerging anticancer agent.

Authors:  Eswar Shankar; Aditi Goel; Karishma Gupta; Sanjay Gupta
Journal:  Curr Pharmacol Rep       Date:  2017-10-14

5.  Preferential star strand biogenesis of pre-miR-24-2 targets PKC-alpha and suppresses cell survival in MCF-7 breast cancer cells.

Authors:  Elizabeth C Martin; Steven Elliott; Lyndsay V Rhodes; James W Antoon; Claire Fewell; Yun Zhu; Jennifer L Driver; Mona Jodari-Karimi; Christopher W Taylor; Erik K Flemington; Barbara S Beckman; Bridgette M Collins-Burow; Matthew E Burow
Journal:  Mol Carcinog       Date:  2012-08-21       Impact factor: 4.784

Review 6.  Role of ER-α36 in breast cancer by typical xenoestrogens.

Authors:  Jun Liu; Zhixiang Xu; Xiaodong Ma; Bin Huang; Xuejun Pan
Journal:  Tumour Biol       Date:  2015-09-04

7.  MEK5/ERK5 signaling suppresses estrogen receptor expression and promotes hormone-independent tumorigenesis.

Authors:  James W Antoon; Elizabeth C Martin; Rongye Lai; Virgilo A Salvo; Yan Tang; Ashley M Nitzchke; Steven Elliott; Seung Yoon Nam; Wei Xiong; Lyndsay V Rhodes; Bridgette Collins-Burow; Odile David; Guandi Wang; Bin Shan; Barbara S Beckman; Kenneth P Nephew; Matthew E Burow
Journal:  PLoS One       Date:  2013-08-09       Impact factor: 3.240

8.  Bioinformatics and in vitro experimental analyses identify the selective therapeutic potential of interferon gamma and apigenin against cervical squamous cell carcinoma and adenocarcinoma.

Authors:  Pei-Ming Yang; Chia-Jung Chou; Ssu-Hsueh Tseng; Chien-Fu Hung
Journal:  Oncotarget       Date:  2017-07-11

Review 9.  An update of Nrf2 activators and inhibitors in cancer prevention/promotion.

Authors:  Farhad Pouremamali; Amir Pouremamali; Mehdi Dadashpour; Narges Soozangar; Farhad Jeddi
Journal:  Cell Commun Signal       Date:  2022-06-30       Impact factor: 7.525

Review 10.  microRNA strand selection: Unwinding the rules.

Authors:  Jeffrey C Medley; Ganesh Panzade; Anna Y Zinovyeva
Journal:  Wiley Interdiscip Rev RNA       Date:  2020-09-20       Impact factor: 9.957

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.